EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis

Jennifer H Ku, Emily Henkle, Kathleen F Carlson, Miguel Marino, Sarah K Brode, Theodore K Marras, Kevin L Winthrop

CHEST · 2024

DOI: 10.1016/j.chest.2023.12.006 ↗

Kurz gefasst

Leitlinie in der Zeitschrift CHEST, 2024. Verfasst von Jennifer H Ku und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Portland State University School of Public Health, Portland, OR; Department of Research & Evaluation, Kaiser Perm…. Hauptthemen laut MEDLINE: Mycobacterium avium-intracellulare Infection, Bronchiectasis, Anti-Bacterial Agents, Medicare. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Nontuberculous mycobacteria are environmental organisms that are increasingly causing chronic and debilitating pulmonary infections, of which Mycobacterium avium complex (MAC) is the most common pathogen. MAC pulmonary disease (MAC-PD) is often difficult to treat, often requiring long-term multidrug antibiotic therapy. RESEARCH QUESTION: Is there an association between various guideline-based three-drug therapy (GBT) regimens and (1) therapy-associated adverse events or (2) regimen change/discontinuation, within 12 months of therapy initiation? STUDY DESIGN AND METHODS: In a retrospective cohort study, we examined tolerability outcomes of GBT regimens for MAC-PD in 4,626 US Medicare beneficiaries with bronchiectasis, who were prescribed a GBT as initial antibiotic treatment for presumed MAC-PD during 2006 to 2014. Using multivariable Cox proportional hazard regression, we estimated adjusted hazard ratios (aHRs) to compare the risk of adverse events and regimen change/discontinuations within 12 months of therapy initiation in various GBT regimens. RESULTS: The cohort had a mean age ± SD of 77.9 ± 6.1 years at treatment start, were mostly female (77.7%), and were mostly non-Hispanic White (87.2%). The risk of regimen change/discontinuation within 12 months of therapy was higher for clarithromycin-based regimens than azithromycin-based regimens (aHR, 1.12; 95% CI, 1.04-1.20 with rifampin; aHR, 1.11; 95% CI, 0.93-1.32 with rifabutin as the companion rifamycin), and for rifabutin-containing regimens than rifampin-containing regimens (aHR, 1.49; 95% CI, 1.33-1.68 with azithromycin; aHR, 1.47; 95% CI, 1.27-1.70 with clarithromycin as the companion macrolide). The aHR comparing regimen change/discontinuation with clarithromycin-ethambutol-rifabutin and azithromycin-ethambutol-rifampin was 1.64 (95% CI, 1.43-1.64). INTERPRETATION: Overall, an azithromycin-based regimen was less likely to be changed or discontinued than a clarithromycin-based regimen, and a rifampin-containing regimen was less likely to be changed or discontinued than a rifabutin-containing regimen within 12 months of therapy start. Our work provides a population-based assessment on the tolerability of multidrug antibiotic regimens used for the treatment of MAC-PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium avium-intracellulare InfectionBronchiectasisAnti-Bacterial AgentsMedicareMycobacterium avium ComplexDrug Therapy, CombinationHumansUnited StatesFemaleMaleAgedRetrospective StudiesPractice Guidelines as TopicRifabutinRifampinAzithromycinAged, 80 and overClarithromycinEthambutolTreatment OutcomeSocieties, Medical

Stichwörter der Autor:innen

MedicareMedicare claimsMycobacterium avium complexantibiotic therapynontuberculous mycobacterial infection

Substanzen

Anti-Bacterial AgentsRifabutinRifampinAzithromycinClarithromycinEthambutol

Autor:innen und Institutionen

  • Oregon Health & Science University, Portland State University School of Public Health, Portland, OR; Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA. Electronic address: jen.h.ku…
  • Oregon Health & Science University, Portland State University School of Public Health, Portland, OR.
  • Oregon Health & Science University, Portland State University School of Public Health, Portland, OR; Center to Improve Veteran Involvement in Care, Veterans Affairs Portland Healthcare System, Portland, OR.
  • University Health Network and University of Toronto, Toronto, ON, Canada.

Zitieren

APA

Ku, J. H., Henkle, E., Carlson, K. F., Marino, M., Brode, S. K., Marras, T. K., & Winthrop, K. L. (2024). Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis. CHEST. https://doi.org/10.1016/j.chest.2023.12.006

Vancouver

Ku JH, Henkle E, Carlson KF, Marino M, Brode SK, Marras TK, et al. Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis. CHEST. 2024. doi:10.1016/j.chest.2023.12.006

BibTeX
@article{Ku2024,
  author = {Ku, Jennifer H and Henkle, Emily and Carlson, Kathleen F and Marino, Miguel and Brode, Sarah K and Marras, Theodore K and Winthrop, Kevin L},
  title = {Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis},
  journal = {CHEST},
  year = {2024},
  doi = {10.1016/j.chest.2023.12.006}
}
Kostenlos starten →